Wang CL, et al. - In this cohort study with 8,356 atrial fibrillation patients who received oral anticoagulants (age, 77.0±7.3 years; 48.0% women), researchers assessed the safety and effectiveness of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation and anemia. This investigation was based on electronic medical records and was performed between 2010 to 2017 at a multicenter healthcare provider in Taiwan. According to findings, lower bleeding risks were observed in relation to NOAC vs warfarin in patients with atrial fibrillation with hemoglobin <10 g/dL; the risk of ischemic stroke/systemic embolism or mortality did not differ.